“Second phase of trial will come to the U.S. (and Rochester) in the middle of 2010, if the FDA agrees to it”
Dear 1 to 2 million cardiac patients who die per year. Good news, Phase 2 of the trial is coming in 2010 and phase 4 of the trial will be finished in about another 5 years…oh, right, you’ll be dead by then. Never mind.
In the meantime, Germany, Thailand, etc. have been successfully treating heart disease with adult stem cells for almost a decade. – DG
3/5/2009 8:05:03 AM -By Jeff Kiger
Backed by Mayo Clinic research and investment, a Belgium biotechnology firm is testing a new treatment using stem cells to repair hearts,.
Cardio3 Biosciences recently launched a Phase II/III clinical study of C-Cure, its new cardiac disease treatment, in Belgium and Germany. While the length of the trial depends on getting patients enrolled, it has started with the first human already undergoing the treatment.
“It is a really big step,” said Cardio3 CEO Dr. Christian Homsy from his Belgium office this week.
Under a collaborative research and licensing agreement with Mayo Clinic, Cardio3 has developed process to “differentiate” stem cells taken from a patient’s own bone marrow to grow into new heart cells and repair diseased or malformed hearts.
C-Cure is based on research by Prof. Andre Terzic and Dr. Atta Behfar at Mayo Clinic. Terzic is one of the principal investigators for the clinical study.
“Second phase of trial will come to the U.S. (and Rochester) in the middle of 2010, if the FDA agrees to it,” Homsy says.
via Postbulletin.com: Rochester, MN.
